Cholera, a life-threatening diarrheal disease, is caused by *Vibrio cholerae* O1, or more rarely O139, serogroup bacteria that produce cholera toxin (CTX) and induce rapid massive loss of body fluids (1). Cholera has been a serious public health problem since its introduction into Africa in 1970, during the seventh cholera pandemic (2). This pandemic, caused by the novel *V. cholerae* O1 lineage El Tor (seventh pandemic El Tor), began in Indonesia in 1961 (2,3). After 60 years, ≈2.9 million cholera cases and ≈95,000 deaths still occur annually (4,5). During 2009–2012, nearly 60% of global cholera cases and deaths occurred in sub-Saharan Africa, but North Africa was considered cholera-free (5).

Algeria is a large country (2,381,741 km²) in North Africa (6). The World Bank (https://www.worldbank.org) ranks Algeria as the third largest economy in the Middle East and North Africa region. In 2018, Algeria had ≈42.2 million inhabitants, ≈30.6 million of whom lived in urban areas (Macro trends LLC, https://www.macrotrends.net).

Algeria reported cholera cases to the World Health Organization from 1971 (1,332 cases, 110 deaths) through 1994 (118 cases, 4 deaths), with a peak in 1979 (2,513 cases, 94 deaths) (Global Health Observatory, https://www.who.int/data/gho) (Figure 1). After a lull of >20 years, on August 23, 2018, the country’s ministry of health announced a cholera outbreak in north Algeria (7). During August 7–September 27, 2018, Algeria reported 291 suspected cholera cases, including 270 persons who were hospitalized, in 7 wilayas (provinces): 6 in north-central Algeria (Bouira, Blida, Algiers, Tipaza, Aïn Defla, and Médéa) and 1 in northwest Algeria (Oran).

We used conventional microbiology and whole-genome sequencing to characterize virulence and antimicrobial resistance of clinical and environmental isolates collected during this outbreak. We also performed a phylogenomic analysis of >1,200 seventh pandemic El Tor genomes to determine whether the 2018 outbreak in Algeria was caused by a sublineage previously circulating in the country, a sublineage circulating in sub-Saharan Africa, or a new sublineage imported from elsewhere.
samples from hospitals or hygiene laboratories in 7 wilayas, 277 from suspected case-patients and 418 from case-contacts, as well as 24 clinical isolates (14 from patients and 10 from case-contacts) and 5 environmental isolates (2 from wastewater, 2 from public drinking water sources, and 1 from stored water) for confirmation. In all, we confirmed 97/291 (33.3%; 95% CI 28.2%–38.9%) suspected cases as *V. cholerae* O1 El Tor serotype Ogawa carrying the *ctxA* gene and 29/428 (6.8%; 95% CI 4.8%–9.6%) case-contacts as asymptomatic carriers. Of the 5 environmental isolates, we also confirmed 2 from wastewater and 1 from stored water as serotype Ogawa.

All *V. cholerae* O1 isolates had the same antimicrobial resistance profile: resistance to streptomycin, sulfamethoxazole, trimethoprim, sulfamethoxazole/trimethoprim, nalidixic acid; decreased susceptibility to ciprofloxacin; and intermediate resistance to chloramphenicol and nitrofurantoin (Table). However, isolates were susceptible to doxycycline, azithromycin, β-lactams, and colistin.

![Figure 1. Cholera cases and seventh pandemic *Vibrio cholerae* O1 biotype El Tor sublineages, Algeria, 1971–2018. A) Number of cholera cases reported to the World Health Organization (WHO) by Algeria per year. For 2018, no cases were reported to WHO, but 291 suspected cases are indicated. B) Number of sequenced genomes detected from various sublineages per year of isolation. Orange circles indicate AFR1, green indicate AFR7, blue indicates AFR 8, purple AFR9, gold AFR14. Numbers in circles indicate the number of isolates.](image)

**Table.** Characteristics of *Vibrio cholerae* O1 epidemic strain, Algeria, 2018*

| Category                        | Strain characteristic                                      |
|--------------------------------|------------------------------------------------------------|
| Serogroup, serotype, biotype    | O1, Ogawa, El Tor                                          |
| Genomic wave                    | 3                                                          |
| Sublineage                      | Seventh pandemic *V. cholerae* O1 biotype El Tor           |
| Genetic markers                 | *ctxB*7, *tcpA*<sup>CRS101</sup>, *VSP*-IIΔ‡              |
| AMR profile, antimicrobial drug (MIC)† |                                           |
| Streptomycin (64–128 mg/L)      | Resistant                                                  |
| Sulfamethoxazole (1,024 mg/L)   | Resistant                                                  |
| Trimethoprim/sulfamethoxazole (32 mg/L) | Resistant                                             |
| Trimethoprim (32 mg/L)          | Resistant                                                  |
| Chloramphenicol (16 mg/L)       | Intermediate                                               |
| Nalidixic acid (256 mg/L)       | Resistant                                                  |
| Ciprofloxacin (0.25 mg/L)       | Decreased susceptibility                                   |
| Nitrofurantoin (64 mg/L)        | Intermediate                                               |
| Colistin (2 mg/L)               | Susceptible                                                |
| Horizontally acquired AMR elements | ICEVchInd5                                                |
| Horizontally acquired AMR genes | *strAB, floR, sul2, dfrA1*                                |
| Chromosomal gene mutations, AMR phenotype |                                           |
| *gyrA*<sub>S83I</sub> and *parC*<sub>S85L</sub> | Resistance to nalidixic acid; decreased susceptibility to ciprofloxacin |
| *nfsA*<sub>R169C</sub> and *nfsB*<sub>Q5Stop</sub> | Intermediate susceptibility to nitrofurantoin           |
| *vprA*<sub>D89N</sub>           | Susceptibility to colistin                                 |

*Data were collected from 20 sequenced outbreak isolates. AMR, antimicrobial resistance; ICEVchInd5, integrative conjugative element of the SXT/R391 family; VSP-IIΔ, deletion in *Vibrio* seventh pandemic island II.†MICs according to Clinical and Laboratory Standards Institute (https://clsi.org/media/1450/m45ed3_sample.pdf).‡Deletion encompassing VC_0495-0512 according to GenBank accession no. AE003852.
We used whole-genome sequencing, comparative genomics, and phylogenetic analysis to characterize a selection of 20 V. cholerae O1 isolates, 17 clinical and 3 environmental (Appendix 1 Tables 2, 3; Appendix 2). We placed these isolates in context with a global collection of 1,265 seventh pandemic El Tor genomic sequences (Appendix 1 Table 4), including 23 isolates collected in Algeria during

Figure 2. Phylogenomic analyses of Vibrio cholerae O1 El Tor isolates from Algeria, 2018. A) Maximum-likelihood phylogeny for 1,285 seventh pandemic V. cholerae biotype El Tor genomic sequences. A6 was used as the outgroup (Appendix 1, Table 4, https://wwwnc.cdc.gov/EID/article/28/6/21-2451-App1.xlsx). Genomic waves and acquisition of ctxB7 allele are indicated. Sublineages previously introduced into Africa (AFR1, AFR3–AFR13) are shown at the right of the tree. Column 1 indicates the geographic origins of the isolates; column 2 indicates isolates from the 2018 cholera outbreak in Algeria, all of which belong to a new seventh pandemic wave 3 sublineage AFR14. B) Maximum-likelihood phylogeny for 115 wave 3 ctxB7 isolates belonging to the distal part of the tree in panel A. N16961 was used as the outgroup (Appendix 1, Table 4). The isolates belonging to AFR14 from the 2018 cholera outbreak in Algeria are shown in red. Acquisition of the polymyxin susceptibility–associated single nucleotide variant in vprA (D89N) is indicated. Blue dots indicate bootstrap values >90%. Scale bars indicate the number of nucleotide substitutions per variable site.
1971–1997. We constructed a maximum-likelihood phylogeny of 1,285 genomes with 10,339 single-nucleotide variants (SNVs) evenly distributed over the nonrepetitive, nonrecombinant core genome. All the isolates recovered in Algeria during 2018 belonged to the seventh pandemic El Tor lineage and clustered in the wave 3 clade containing isolates carrying the ctxB7 allele (Figure 2, panel A) (3). The 2018 isolates did not belong to sublineages previously found in Algeria, including AFR1, which circulated during the 1970s and early 1980s; AFR7, which circulated during the mid- to late-1980s and early 1990s; or AFR8 and AFR9, which circulated during the mid- to late-1990s (Figures 1, 2) (8). The 2018 isolates also did not belong to other sublineages found in Africa, including the most recently introduced AFR13 sublineage, previously known as T13 (8–11). AFR13 has been circulating in eastern Africa since 2015 and in Yemen since 2016 (Figure 1). A second phylogeny, restricted to 115 wave 3 ctxB7 isolates from the distal part of the global tree, showed the 2018 isolates from Algeria are closely related to isolates from South Asia collected during 2017–2018 in India and Bangladesh (Figure 2, panel B). This finding suggests the 2018 cholera outbreak in Algeria was cause by a newly imported strain (sublineage AFR14) from South Asia, rather than resurgence of any sublineage previously in Algeria or introduction of a sublineage circulating elsewhere in Africa.

The median pairwise distance between the 20 isolates recovered during the 2018 outbreak was 2.5 (range 0–8) core-genome SNVs. All 20 isolates had similar genomic features (Table), including the toxin-coregulated pilus subunit A gene variant, tcpA1385, a deletion (∆VC_0495–0512) in the Vibrio seventh pandemic island II (VSP-II), and an SXT/R391 integrating conjugating element (ICE), called ICEVchInd5, encoding resistance to streptomycin (strAB), sulfonamides (sul2), trimethoprim (dfrA1), sulfamethoxazole/trimethoprim (dfrA1 and sul2), and intermediate resistance to chloramphenicol (floR) (8). The Algeria isolates had mutations of VC_0715, resulting in the R169C substitution, and VC_A0637, resulting in the premature stop codon (Q5Stop) conferring intermediate nitrofurazan resistance. Isolates also had mutations of the DNA gyrase, gyrA (S83I), and topoisomerase IV, parC (S85L), genes conferring resistance to nalidixic acid and decreased susceptibility to ciprofloxacin (8,9). In addition, isolates had a specific nonsynonymous SNV in the vprA gene (VC_1320), which resulted in the D89N substitution, conferring susceptibility to polymyxins (9), as reported for the AFR13 sublineage, although resistance to polymyxin B has been used as a marker of V. cholerae O1 biotype El Tor since the seventh pandemic began (12).

Conclusions
The seventh pandemic El Tor wave 3 clade, containing isolates carrying the ctxB7 allele, emerged in South Asia earlier this century (9,13) and has been exported from Asia ≥4 times: to West Africa in 2007 (AFR12 sublineage) (8), Haiti in 2010 (14), East Africa in 2013–2015 (AFR13) (9,10), and now North Africa (AFR14). Polymyxin-susceptible seventh pandemic El Tor isolates with a vprA mutation encoding the D89N substitution were identified in South Asia in 2012 (15), spread to Eastern Africa and Yemen (AFR13) (9,10), and then spread to Algeria (AFR14).

Algeria controlled disease spread more swiftly in 2018 than during previous seventh pandemic El Tor introductions. The ministry of health led the epidemic response, initiated an emergency action plan at national and local levels, and enhanced epidemiologic surveillance and reporting. A health surveillance unit coordinated response actions and implemented recommendations. Designated hospitals managed suspected case-patients in isolation wards. Persons with suspected V. cholerae were hospitalized, isolated, rehydrated, and treated with doxycycline, erythromycin, azithromycin, ceftriaxone, or ciprofloxacin; patients were released only after a negative V. cholerae culture. Case-contacts were systematically screened, and asymptomatic carriers received chemoprophylaxis. In affected areas, the ministry of health reinforced bacteriologic monitoring of water sources, including drinking water, bore holes, wells, springs, and wadi (ravines that are dry except during rainy seasons), and took corrective action for sources with poor bacteriologic quality.

In summary, V. cholerae O1 isolates collected during a 2018 cholera outbreak in Algeria were a seventh pandemic El Tor sublineage, AFR14, newly introduced into Africa from South Asia. Our findings suggest that, in addition to appropriate control and prevention measures during outbreaks, such as those used in Algeria, reducing the burden of cholera in South Asia might aid in long-term control of cholera in Africa.

Acknowledgments
We thank all the participants and particularly Hamza Letlout of Public Health Facility of Tipaza and Ahlem Toua of Institut Pasteur of d’Algérie, Annex of Oran, for sending stool samples or Vibrio cholerae strains and Abdelali Meftah of Public Hospital Establishment of Boufarik for his assistance during this epidemic.
Outbreak of *Vibrio cholerae* O1 El Tor, Algeria

This work was supported by the Pasteur Institute of Algeria, Institut Pasteur, and by the French Government’s Investissement d’Avenir program, Laboratoire d’Excellence, Integrative Biology of Emerging Infectious Diseases (grant no. ANR-10-LABX-62-IBEID).

About the Author

Dr. Benamrouche is a medical microbiologist, head of the Enterobacteria Laboratory at the Pasteur Institute of Algeria, Algiers, Algeria, Pasteur International Network, and a senior lecturer on the Faculty of Medicine, University of Algiers I, Algiers, Algeria. Her research interests include the surveillance and epidemiology of enteric bacterial pathogens and antimicrobial resistance.

References

1. Clemens JD, Nair GB, Ahmed T, Qadri F, Holmgren J. Cholera. Lancet. 2017;390:1539–49. https://doi.org/10.1016/S0140-6736(17)30559-7
2. Barua D, Greenough WB, editors. Cholera. New York: Plenum; 1992.
3. Mutreja A, Kim DW, Thomson NR, Connor TR, Lee JH, Kariuki S, et al. Evidence for several waves of global transmission in the seventh cholera pandemic. Nature. 2011;477:462–5. https://doi.org/10.1038/nature10392
4. World Health Organization. Cholera key facts [cited 2022 Mar 25]. https://www.who.int/news-room/fact-sheets/detail/cholera
5. Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9:e0003832. https://doi.org/10.1371/journal.pntd.0003832
6. United Nations. Algeria country profile [cited 2022 Mar 25]. http://data.un.org/en/iso/dz.html
7. Reliefweb. WHO: cholera — Algeria (14 September 2018) [cited 2022 Mar 25]. https://reliefweb.int/report/algeria/who-cholera-algeria-14-september-2018
8. Weill FX, Domman D, Njamkepo E, Tarr C, Rauzier J, Fawal N, et al. Genomic history of the seventh pandemic of cholera in Africa. Science. 2017;358:785–9. https://doi.org/10.1126/science.aad5901
9. Weill FX, Domman D, Njamkepo E, Almesbahi AA, Naji M, Nasher SS, et al. Genomic insights into the 2016–2017 cholera epidemic in Yemen. Nature. 2019;565:230–3. https://doi.org/10.1038/s41586-018-0818-3
10. Mashe T, Domman D, Tarupiwa A, Manangazira P, Phiri I, Masunda K, et al. Highly resistant cholera outbreak strain in Zimbabwe. N Engl J Med. 2020;383:687–9. https://doi.org/10.1056/NEJM62004773
11. Oprea M, Njamkepo E, Cristea A, Zhukova A, Clark CG, Kravetz AN, et al. The seventh pandemic of cholera in Europe revisited by microbial genomics. Nat Commun. 2020;11:5347. https://doi.org/10.1038/s41467-020-19185-y
12. Herrera CM, Crofts AA, Henderson JC, Pingali SC, Davies BW, Trent MS. The *Vibrio cholerae* VprA-VprB two-component system controls virulence through endotoxin modification. MBio. 2014;5:e02283–14. https://doi.org/10.1128/mBio.02283-14
13. Naha A, Pazhani GP, Ganguly M, Ghosh S, Ramamurthy T, Nandy RK, et al. Development and evaluation of a PCR assay for tracking the emergence and dissemination of Haitian variant ctxB in *Vibrio cholerae* O1 strains isolated from Kolkata, India. J Clin Microbiol. 2012;50:1733-6. https://doi.org/10.1128/JCM.00387-12
14. Domman D, Quilici ML, Dorman MJ, Njamkepo E, Mutreja A, Mather AE, et al. Integrated view of *Vibrio cholerae* in the Americas. Science. 2017;358:789–93. https://doi.org/10.1126/science.aao2136
15. Samanta P, Ghosh P, Chowdhury G, Ramamurthy T, Mukhopadhyay AK. Sensitivity to polymyxin B in El Tor *Vibrio cholerae* O1 strain, Kolkata, India. Emerg Infect Dis. 2015;21:2100–2. https://doi.org/10.3201/eid2111.150762

Address for correspondence: Nabila Benamrouche, Institut Pasteur d’Algérie, Route du petit Staoueli Dely Ibrahim, 16000 Alger, Algeria; email: n_benamrouche@yahoo.fr; François-Xavier Weill, Institut Pasteur, 28 rue du Dr Roux, F-75015 Paris, France; email: francois-xavier.weill@pasteur.fr
Outbreak of Imported Seventh Pandemic *Vibrio cholerae* O1 El Tor, Algeria, 2018

Appendix 2

Additional Methods

**Culture, Identification, and Serotyping**

The stool samples were analyzed for confirmation of the presence of *Vibrio cholerae* by standard culture methods (1), except for 10 samples collected from case-contacts for whom a Crystal VC cholera rapid diagnostic test (Arkay, https://www.arkray.co.in) was negative. The cultured bacterial strains were characterized by using the API 20 E identification system (bioMérieux, https://www.biomerieux.com), and serotyping (1).

**Antimicrobial Susceptibility Testing**

Antimicrobial susceptibility testing was determined by the disk diffusion method, on Mueller-Hinton agar, in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines (2). The following antimicrobial drugs were tested using Bio-Rad (https://www.bio-rad.com) cartridges: ampicillin (10 µg), amoxicillin/clavulanic acid (20/10 µg), piperacillin (100 µg), cefazolin (30 µg), cefoxitin (30 µg), cefotaxime (30 µg), ceftazidime (30 µg), cefepime (30 µg), imipenem (10 µg), meropenem (10 µg), nitrofurantoin (300 µg), streptomycin (10 µg), amikacin (30 µg), gentamicin (10 µg), chloramphenicol (30 µg), sulfamethoxazole (300 µg), trimethoprim (5 µg), trimethoprim-sulfamethoxazole (1.25/23.75 µg), tetracycline (30 µg), nalidixic acid (30 µg), ciprofloxacin (5 µg), azithromycin (15 µg), and colistin (10 µg). The MICs of amoxicillin/clavulanic acid, nitrofurantoin, streptomycin, chloramphenicol, sulfamethoxazole, trimethoprim, trimethoprim-sulfamethoxazole, tetracycline, nalidixic acid, and ciprofloxacin were determined with Etests (bioMérieux) on 8 isolates chosen on the basis of city of isolation. The MICs of ampicillin and colistin were determined on the same 8 isolates by the microdilution method, in accordance with CLSI guidelines (2).
CLSI interpretative criteria for the antibiotic susceptibility testing of *Vibrio* spp. (M45 document) were used when available (2). For trimethoprim, nitrofurantoin, nalidixic acid, ciprofloxacin, and colistin the interpretative criteria for Enterobacteriaceae/*Salmonella* spp. (M100-S30 document) were used (3). Interpretive criteria for streptomycin, not available in the M45 and M100 documents, were used as follow: susceptibility ≤16 mg/L and resistance ≥32 mg/L. Quality control for the antimicrobial susceptibility analysis was performed with *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 (for carbapenems), as recommended by CLSI guidelines (2).

**Total DNA Extraction and Detection of the Cholera Toxin Gene by PCR**

Total DNA was extracted with the Purelink Genomic DNA mini Kit (Thermo Fisher Scientific, https://www.thermofisher.com), in accordance with the manufacturer's recommendations.

A conventional PCR simplex assay for detection of the *ctxA* gene (primers: CTX2: 5′-CGGGCAGATTCTAGACCTCCTG-3′ and CTX3: 5′-CGATGATCTTGGAGCATTCCCAC-3′) was performed, as previously described (4).

**Selection of *Vibrio cholerae* O1 Strains for Genome Sequencing**

Twenty *V. cholerae* O1 isolates collected at different times, from different places, and sources during the 2018 outbreak were selected for study by the Pasteur Institute of Algeria. Their total DNA extracts were sent to the French National Reference Center for Vibrios and Cholera (FNRCVC), Institut Pasteur, Paris, France for genomic analyses. In addition, total DNA extracts from three *V. cholerae* O1 isolates collected in Algeria in 1992 were also sent to the FNRCVC.

**Whole-Genome Sequencing**

We analyzed 43 *V. cholerae* O1 biotype El Tor isolates from Algeria by whole-genome sequencing (Appendix 1 Table 4). Fourteen of these isolates collected between 1974 and 1997 were sequenced in a previous study (5). The 29 *V. cholerae* O1 biotype El Tor isolates sequenced here consisted of the 20 isolates from 2018, 2 from 1980, 2 from 1981, 3 from 1992, and 2 from 1997. The isolates from 1980, 1981, and 1997 were from the collection of the FNRCVC and
their total DNA was extracted with the Maxwell 16-cell DNA purification kit (Promega, https://www.promega.com) in accordance with the manufacturer's recommendations.

Whole-genome sequencing was carried out at the P2M sequencing platform of the Institut Pasteur, and at the genotyping and sequencing core facility of the Institut du Cerveau (Paris, France), on Illumina (https://www.illumina.com) platforms generating 150 bp paired-end reads, yielding a mean coverage of 276-fold (minimum 123-fold, maximum 389-fold).

Additional Genomic Data

Raw sequence files and assembled genomes from 1,257 7PET strains were downloaded from the European Nucleotide Archive (ENA) or GenBank databases and included in this study (Appendix 1 Table 4).

Genomic Sequence Analyses

The paired-end reads and draft or assembled genomes were mapped onto the reference genome of *Vibrio cholerae* O1 El Tor N16961, also known as A19 (GenBank accession nos. LT907989 and LT907990) with Snippy version 4.6.0/BWA version 0.7.17 (https://github.com/tseemann/snippy). Single-nucleotide variants (SNVs) were called with Snippy version 4.6.0/Freebayes version 1.3.2 under the following constraints: mapping quality of 60, a minimum base quality of 13, a minimum read coverage of 4, and a 75% read concordance at a locus for a variant to be reported. An alignment of core genome SNVs was produced in Snippy for phylogeny inference.

Short reads were assembled with SPAdes version 3.15.2 (6). The various genetic markers were analyzed with BLAST version 2.2.26 against reference sequences of the O1 *rfb* gene, *ctxB*, *wbeT*, and the whole locus of VSP-II, as previously described (5).

The presence and type of acquired antimicrobial resistance genes (ARGs) or ARG-containing structures were determined with ResFinder version 4.0.1 (https://cge.cbs.dtu.dk/services/ResFinder), BLAST analysis against GI-15, Tn7, and SXT/R391 integrative and conjugative elements, and PlasmidFinder version 2.1.1 (https://cge.cbs.dtu.dk/services/PlasmidFinder). The presence of mutations in the genes encoding resistance to quinolones (*gyrA*, *parC*), resistance to nitrofurans (*VC_0715* and *VC_A0637*), or
restoring susceptibility to polymyxin B (vprA) was investigated by manual analysis of the sequences assembled de novo with BLAST, as previously described (5,7).

**Phylogenetic Analysis**

Repetitive (insertion sequences and the TLC-RS1-CTX region) and recombinogenic (VSP-II) regions in the alignment were masked (5). Putative recombinogenic regions were detected and masked with Gubbins version 2.4.1 (8). A maximum-likelihood (ML) phylogenetic tree was built from an alignment of 10,339 chromosomal SNVs, with RAxML version 8.2.12, under the GTR model with 200 bootstraps (9). This global tree was rooted on the A6 genome, and visualized with Interactive Tree of Live (iTOL) version 5 (https://itol.embl.de) (10). A second phylogenetic analysis was performed with the same methodology on 115 wave 3 ctxB7 isolates, including all 20 isolates from the 2018 Algerian outbreak, belonging to the distal part of the global tree. This ML tree was built from an alignment of 506 chromosomal SNVs, rooted on the N16961 genome, and visualized with iTOL version 5.

**Data Availability**

Short-read sequence data were submitted to the ENA database (http://www.ebi.ac.uk/ena), under study accession number PRJEB48258 and their accession numbers are provided in Appendix 1 Table 4.

**References**

1. Centers for Disease Control and Prevention. Laboratory methods for the diagnosis of *Vibrio cholerae* Atlanta: The Centers; 1994. https://www.cdc.gov/cholera/pdf/laboratory-methods-for-the-diagnosis-of-vibrio-cholerae-chapter-6.pdf

2. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline. 3rd edition (CLSI guidelines M45). Wayne (PA): the Institute; 2016.

3. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 30th edition. CLSI supplement M100. Wayne (PA): the Institute; 2020.
4. Fields PI, Popovic T, Wachsmuth K, Olsvik O. Use of polymerase chain reaction for detection of toxigenic *Vibrio cholerae* O1 strains from the Latin American cholera epidemic. J Clin Microbiol. 1992;30:2118–21. PubMed https://doi.org/10.1128/jcm.30.8.2118-2121.1992

5. Weill FX, Domman D, Njamkepo E, Tarr C, Rauzier J, Fawal N, et al. Genomic history of the seventh pandemic of cholera in Africa. Science. 2017;358:785–9. PubMed https://doi.org/10.1126/science.aad5901

6. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:455–77. PubMed https://doi.org/10.1089/cmb.2012.0021

7. Weill FX, Domman D, Njamkepo E, Almesbahi AA, Naji M, Nasher SS, et al. Genomic insights into the 2016–2017 cholera epidemic in Yemen. Nature. 2019;565:230–3. PubMed https://doi.org/10.1038/s41586-018-0818-3

8. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, et al. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. Nucleic Acids Res. 2015;43:e15. PubMed https://doi.org/10.1093/nar/gku1196

9. Stamatakis A. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics. 2006;22:2688–90. PubMed https://doi.org/10.1093/bioinformatics/btl446

10. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v4: recent updates and new developments. Nucleic Acids Res. 2019;47(W1):W256–9. PubMed https://doi.org/10.1093/nar/gkz239